ERBB2 and breast carcinoma: Despite promising clinical benefits in both advanced disease and neoadjuvant settings [32–36], a substantial proportion of HER2+ breast cancers show a proclivity toward resistance or become refractory to HER2-targeted therapies, including trastuzumab, which has been a major challenge with the use of these drugs [53, 54].